The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dr Walts has his fingerprints all over recent developments at Hemogenyx, just because its not spelt out in black and white it should be obvious the achievements to date if people care to look. He has been slated to look for non dilutive funding which is funding without the issuance of shares or Convertable Loan Notes which have worked so well for the company in the past.
Pre clinical grants are available but very small and with alot of hoops to jump though, when they are clinical and announce start of trials it becomes alot easier to just get free money. So...
As far as I see it the company had 2 options, sacrifice one of the candidates and accept very low ball offers to licence something to pay for other products
OR
Partner up in the most cost efficient agreements possible:
1, Hemogenyx Pharmaceuticals Partnership with Selexis : I take it nobody else bothered to do any research on their other licencing agreements? Well I did, quite a few examples out there, its likely they have charged Hemogenyx about £30k up front and will defer the rest of any costs for production of antibodies until milestones have been reached which can mean they pay nothing until they licence, at which point they could have to pay a few hundred thousand. Tiny cost to Hemogenyx but huge benefit this is as good and equivalent to non dilutive funding.
2, Hemo-CAR-T partnership with WuXi ATU: again, go and research them, they INVEST in seed rounds, they dont take money off a tiny company like Hemo. Again having not seen the paperwork its based on precedent from other licencing agreements but its likely Hemo are not paying them anything but will instead sign some sort of deal when there is clinical proof.
Its semantics but not spending money is alot better than trying to raise non dilutive cash just to pay it to some other company to provide the services being provided by WuXi and Selexis.
Thank you Hedge and Learn, it is draining spending time responding to people who profess to being investors but just want to post negative posts. Sometimes, fine its justified but this time? Having a dig because Vlad is going to a Conference in the UK to tell investors about Hemogneyx when the company is listed in the UK?
I'm with JHFH, I'm a LTH and It's great to hear Vlad is on the road and participating at the conference. It's what I want him to be doing in parallel with advancing the candidates into the clinic.
I'll take JHFH's positivity above negativity any day of the week. Infact, most of his positive posts are purely here to offer the balance from the ridiculous snipes from the usual suspects.
I think you either have to TRUST Vlad or not. If it's a not, go elsewhere.
You always try and see the positive in Vlad even when he is wrong...
How many conferences is this now we have been too and never get any feedback ..is that why we engaged Mr Walt's for To open doors ..
How are we doing with government discussions ???
Agree with you JHFH, I am sure that is what he thinks and why he is telling us about this.
Pumpkin, nice, wee snide digs, classy! HT I guess its all about scale, if the company was Pfizer or J&J or Merck then it would be expected they attend conferences in their respective fields. Hemogenyx is tiny so to be one of the few presenting at a big conference like this has the potential to significantly improve visibility and with that external investment and licencing opportunities. Did it necessarily require an RNS? Maybe not, but if he had done it via twitter he would have gotten abuse for not doing it officially so he really is in a no win situation, be nice if people could give credit where credit is due.
He is getting to the UK, the market where Hemogenyx shares are listed, he is getting in front of his peers to promote and advertise his company and he has told us about it in an official manner.
Seriously, if you both are investors in this company and want it to do well would it not be a nice change to instead of having a dig at every single opportunity just say something like "Good luck Vlad, hope it goes well"??
He has plenty of money in bank;1st class flights from THE USA?
Not another RNS for a bloody conference ...
Does he really need to release one for such a thing...I thought he was frugal ??
Just had a look, he will be in good company, some very big well known names and some unknown names but big companies none the less.
Been complaining for a while now that despite all the good and positive news nobody outside of his existing investor pool is seeing his updates. This is a face to face presentation in the UK, experts in the field, not a poster session bit a captive audience being told that Hemogenyx have a treatment and they are taking it clinical in the very near future.
Think your right about the networking Trek, a big part of this, looked at the time table and there are lots of big names and lots of opportunities to rub shoulders with some powerful people in the field. I am sure Vlad will also be talking to people about CBR.
Worst case scenario? Few more people and companies in the UK get exposure to what has to date been a very USA focused and very cheap pharma company and perhaps a few will invest. Best case scenario? One of those companies takes an interest and down the line it generates a licencing opportunity for CDX/CAR-T or CBR.
Nothing to lose, everything to gain. Lack of visibility has been a real killer for Hemogenyx, the HC wainwright conference in the US did little for the share price so no guarantees this will help much. But its the right conference, in the right country and the right time just as Hemogenyx are on the cusp of going clinical. Good luck Vlad!
From personal experience with these type of events your presentation usually tells a great story but the focus is on what’s next, when and how.
I am hoping that there is news close to all this networking. That’s when 2 and 2 will be likely put together!
Looks like it wants to go higher today.
Can’t beat a bit of anticipation! :-)
Usual caveats
Trek
Can only the positive news from now on.
Bought more ,sit and wait now.
Have a nice day all x
Wouldn’t say game changing… just half an hour appetiser, but the networking will be key with other specialist in same field.
https://www.immuno-oncologyeurope.com/t-cell-therapy
09:35
Anti-FLT3 CAR T and Bispecific Antibody Therapies for Effective Elimination of AML and Conditioning for Hematopoietic Stem Cell Transplantation
“ Vladislav M. Sandler, PhD, CEO & Co-Founder, Hemogenyx Pharmaceuticals
Relapsed/refractory acute myeloid leukemia (R/R-AML) has a poor prognosis even with hematopoietic stem cell (HSC) transplantation. Surface expression of FLT3 in leukemic cells and in HSCs provides an excellent opportunity for the development of targeted therapy aimed to eradicate FLT3+ R/R-AML and facilitate bone marrow conditioning. We have developed chimeric antigen receptor modified T cells (CAR T) targeting FLT3 and a humanized bispecific antibody (CDX) that recruits T cells to eliminate FLT3-expressing cells.”
I also note John Maher from kings college’s slot (day2) may be interesting
https://www.immuno-oncologyeurope.com/t-cell-therapy#Day1
Usual caveats
Trek
This has got to be good news. It gets us out there, makes us more visible. A sense a blue day today. Onwards and upwards
GLA
So that’s why he’s in London then!
Come on Vlad..........please give a brilliant presentation. The platform is there for a game changing event. Good Luck.